Search

Researchers at MSK published updated data today in the New England Journal of Medicine from the ongoing, single-arm Phase II VISION study evaluating tepotinib as a single agent in patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations.

… Friday, May 29, 2020 Researchers at Memorial Sloan Kettering Cancer Center (MSK) published updated data today in the New England Journal of Medicine from the ongoing, single-arm phase II VISION study evaluating tepotinib as a single agent in patients with advanced non-small cell lung cancer (NSCLC) with

Longtime donors Fiona and Stanley Druckenmiller have contributed a transformative gift of $100 million to MSK through their foundation. The gift will be used to launch the Fiona and Stanley Druckenmiller Presidential Innovation Fund.

… Tuesday, January 11, 2022 Memorial Sloan Kettering Cancer Center (MSK) today announced the launch of the Fiona and Stanley Druckenmiller Presidential Innovation Fund. The new initiative, made possible by a transformative $100 million gift from the Fiona and Stanley Druckenmiller Foundation, is expected

Deb Schrag, MD, MPH, gastrointestinal oncologist and Chair of the Department of Medicine, presented results from a randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total surgical excision for the treatment of patients with locally advanced rectal cancer.

… Sunday, June 4, 2023 New data led by researchers at Memorial Sloan Kettering Cancer Center (MSK) and Dana-Farber Brigham Cancer Center featured in the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting press program and simultaneously published in  The New England Journal of Medicine (NEJM

… Thursday, April 3, 2025 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Almudena Chaves Perez, Adriana Mujal, Hina Shah, and Lydia Paraskevi Tsamouri Awarded the 2025 Kravis WiSE Fellowships Almudena Chaves Perez, Adriana Mujal, Hina Shah, and Lydia

This research is important for developing better drugs and screening methods for pancreatic tumors.

… Monday, September 3, 2018 Summary Understanding how pancreatic cancer develops is important for developing better drugs and screening methods. Researchers are finding new clues by studying abnormal pancreas cells that sometimes turn into cancer. One universal truth about cancer is that the later it’s

Learn how genetic analysis of prostate cancer tumors is guiding treatment with checkpoint inhibitor immunotherapy.

… Friday, October 24, 2025 Immunotherapy drugs called  checkpoint inhibitors  are a promising cancer treatment, but so far only a minority of people respond to them. This has been especially notable in the treatment of  prostate cancer , the most common cancer in men, after skin cancer. Researchers at

Patients of European ancestry are more likely to find a match to the latest targeted cancer drugs than patients of other ancestries, according to new MSK research. This trend could exacerbate disparities in cancer outcomes.

… Thursday, January 9, 2025 Nearly half of all new cancer drugs approved by the U.S. Food and Drug Administration (FDA) over the past quarter-century have received that approval based on their ability to target genetic changes driving tumor growth. Medical oncologists use information about the genetic

Researchers from Memorial Sloan Kettering Cancer Center recently discovered that the most frequently used cancer cell lines in ovarian cancer research are not suitable models of ovarian cancer.

… Friday, July 12, 2013 Researchers from Memorial Sloan Kettering Cancer Center recently discovered that the most frequently used cancer cell lines in ovarian cancer research are not suitable models of ovarian cancer. Their findings are the result of a detailed review of genomic data that recently became

The MSK team’s goal was to get at the underlying defects in cells that these mutations cause.

… Monday, July 1, 2019 Summary MSK researchers have made new discoveries about how changes in a family of cancer-causing genes can lead to epigenetic changes. A family of genes called IDH are associated with cancer. These genes make enzymes called isocitrate dehydrogenases. The enzymes help break down

Laboratory studies have revealed an explanation for why androgen-deprivation therapy makes radiation therapy more effective in the treatment of high-risk prostate cancer.

… Thursday, December 12, 2013 Summary Laboratory studies have revealed an explanation for why androgen-deprivation therapy makes radiation therapy more effective in the treatment of high-risk prostate cancer. Sometimes a medical treatment becomes the standard of care before experts are able to explain